Abstract
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Current Pharmaceutical Design
Title:The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Volume: 25 Issue: 8
Author(s): Jiayuan Qu, Mohammad Amjad Kamal and Chengfu Yuan*
Affiliation:
- Department of Biochemistry, China Three Gorges University, Yichang 443002,China
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Abstract:
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Export Options
About this article
Cite this article as:
Qu Jiayuan, Kamal Amjad Mohammad and Yuan Chengfu*, The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer , Current Pharmaceutical Design 2019; 25 (8) . https://dx.doi.org/10.2174/1381612825666190404122154
DOI https://dx.doi.org/10.2174/1381612825666190404122154 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Inhibitors of the Chemokine Receptor CXCR4: Chemotherapy of AIDS, Metastatic Cancer, Leukemia and Rheumatoid Arthritis
Letters in Drug Design & Discovery Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Marine Sesterterpenes: An Overview
Current Organic Chemistry Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors
Current Medicinal Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Novel Targets of Vitamin D Activity in Bone: Action of the Vitamin D Receptor in Osteoblasts, Osteocytes and Osteoclasts
Current Drug Targets Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry